Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
GNI Group ( (JP:2160) ) has issued an update.
GNI Group has sharply revised its full-year 2025 consolidated earnings forecast, now projecting lower revenue of ¥26.8 billion and a swing from a previously expected substantial profit to a net loss, driven mainly by the deferral of the planned NASDAQ listing of core biotech subsidiary Cullgen and the exclusion of an anticipated large listing gain. The company will also recognize an impairment loss of ¥468 million on goodwill, intangible and fixed assets tied to several subsidiaries, while Cullgen’s full-year operating loss will remain fully consolidated instead of shifting to equity-method accounting, further pressuring earnings even as ETUARY® and the Medtech unit continue to post record-high revenues, implying a near-term hit to profitability and equity story despite ongoing operational growth in its core businesses and continued pursuit of Cullgen’s listing.
The most recent analyst rating on (JP:2160) stock is a Hold with a Yen2406.00 price target. To see the full list of analyst forecasts on GNI Group stock, see the JP:2160 Stock Forecast page.
More about GNI Group
GNI Group Ltd. is a Japan-listed biopharmaceutical and medtech company whose core pharmaceutical product is ETUARY®, launched in 2014, and which also markets newer respiratory drug Etorel® (nintedanib). The group operates a growing Medtech business anchored by Berkeley Advanced Biomaterials (BAB), acquired in 2017, with both ETUARY® and BAB delivering consecutive years of record sales, positioning GNI as a niche growth player in respiratory therapies and specialized biomaterials.
Average Trading Volume: 1,290,877
Technical Sentiment Signal: Buy
Current Market Cap: Yen143.8B
See more data about 2160 stock on TipRanks’ Stock Analysis page.